|
1
|
O'Donnell MJ, Xavier D, Liu L, Zhang H,
Chin SL, Rao-Melacini P, Rangarajan S, Islam S, Pais P, McQueen MJ,
et al: Risk factors for ischaemic and intracerebral haemorrhagic
stroke in 22 countries (the INTERSTROKE study): A case-control
study. Lancet. 376:112–123. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Global Burden of Disease Study 2013
Collaborators, : Global, regional, and national incidence,
prevalence, and years lived with disability for 301 acute and
chronic diseases and injuries in 188 countries, 1990-2013: A
systematic analysis for the Global Burden of Disease Study 2013.
Lancet. 386:743–800. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
GBD 2013 Mortality and Causes of Death
Collaborators, : Global, regional, and national age-sex specific
all-cause and cause-specific mortality for 240 causes of death,
1990-2013: A systematic analysis for the Global Burden of Disease
Study 2013. Lancet. 385:117–171. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Walcott BP, Boehm KM, Stapleton CJ, Mehta
BP, Nahed BV and Ogilvy CS: Retrievable stent thrombectomy in the
treatment of acute ischemic stroke: Analysis of a revolutionizing
treatment technique. J Clin Neurosci. 20:1346–1349. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Brainin M, Teuschl Y and Kalra L: Acute
treatment and long-term management of stroke in developing
countries. Lancet Neurol. 6:553–561. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang W, Li M, Chen Q and Wang J:
Hemorrhagic transformation after tissue plasminogen activator
reperfusion therapy for ischemic stroke: Mechanisms, models, and
biomarkers. Mol Neurobiol. 52:1572–1579. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ooboshi H, Ibayashi S, Takada J, Kumai Y
and Iida M: Brain ischemia as a potential target of gene therapy.
Exp Gerontol. 38:183–187. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Moss JA: Gene therapy review. Radiol
Technol. 86:155–184. 2014.PubMed/NCBI
|
|
9
|
Aoki M and Morishita R: Therapeutic
angiogenesis for ischemic diseases. Nihon Rinsho. 64:762–768.
2006.(In Japanese). PubMed/NCBI
|
|
10
|
Gudmundsson GH, Magnusson KP, Chowdhary
BP, Johansson M, Andersson L and Boman HG: Structure of the gene
for porcine peptide antibiotic PR-39, a cathelin gene family
member: comparative mapping of the locus for the human peptide
antibiotic FALL-39. Proc Natl Acad Sci USA. 92:7085–7089. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Muinck ED, Nagy N, Tirziu D, Murakami M,
Gurusamy N, Goswami SK, Ghatpande S, Engelman RM, Simons M and Das
DK: Protection against myocardial ischemia-reperfusion injury by
the angiogenic Masterswitch protein PR 39 gene therapy: the roles
of HIF1alpha stabilization and FGFR1 signaling. Antioxid Redox
Signal. 9:437–445. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Borghouts C, Kunz C, Delis N and Groner B:
Monomeric recombinant peptide aptamers are required for efficient
intracellular uptake and target inhibition. Mol Cancer Res.
6:267–281. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yamawaki H, Haendeler J and Berk BC:
Thioredoxin: A key regulator of cardiovascular homeostasis. Circ
Res. 93:1029–1033. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yoshida T, Nakamura H, Masutani H and
Yodoi J: The involvement of thioredoxin and thioredoxin binding
protein-2 on cellular proliferation and aging process. Ann N Y Acad
Sci. 1055:1–12. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ruan XY, Bi JZ, Liu QY, Zhang SB, Yang GX
and Wang QY: Construction and identification of recombinant
plasmids expressing hTRX-PR39. J Shandong University (Health
Sciences). 47:30–34. 2009.
|
|
16
|
Ruan X, Yuan Z, Du Y, Yang G and Wang Q:
Recombinant adeno-associated virus delivered human thioredoxin-PR39
prevents hypoxia-induced apoptosis of ECV304 cells. Neural Regen
Res. 7:708–713. 2012.PubMed/NCBI
|
|
17
|
Ruan XY, Liang YC, Du B, Lin YT, Guo YD,
Zhao J, Li S, Li JF, Sun QJ and Du YF: Potential role of
recombinant adeno-associated virus human thioredoxin-PR39 in cell
and vascular protection against hypoxia. Exp Ther Med. 9:1605–1610.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Longa EZ, Weinstein PR, Carlson S and
Cummins R: Reversible middle cerebral artery occlusion without
craniectomy in rats. Stroke. 20:84–91. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bederson JB, Pitts LH, Tsuji M, Nishimura
MC, Davis RL and Bartkowski H: Rat middle cerebral artery
occlusion: Evaluation of the model and development of a neurologic
examination. Stroke. 17:472–476. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ross CR, Ricevuti G and Scovassi AI: The
antimicrobial peptide PR-39 has a protective effect against HeLa
cell apoptosis. Chem Biol Drug Des. 70:154–157. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wu J, Parungo C, Wu G, Kang PM, Laham RJ,
Sellke FW, Simons M and Li J: PR39 inhibits apoptosis in hypoxic
endothelial cells: Role of inhibitor apoptosis protein-2.
Circulation. 109:1660–1667. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chan YR and Gallo RL: PR-39, a
syndecan-inducing antimicrobial peptide, binds and affects
p130(Cas). J Biol Chem. 273:28978–28985. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shi J, Ross CR, Leto TL and Blecha F:
PR-39, a proline-rich antibacterial peptide that inhibits phagocyte
NADPH oxidase activity by binding to Src homology 3 domains of p47
phox. Proc Natl Acad Sci USA. 93:6014–6018. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bao J, Sato K, Li M, Gao Y, Abid R, Aird
W, Simons M and Post MJ: PR-39 and PR-11 peptides inhibit
ischemia-reperfusion injury by blocking proteasome-mediated I kappa
B alpha degradation. Am J Physiol Heart Circ Physiol.
281:H2612–H2618. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li J, Post M, Volk R, Gao Y, Li M, Metais
C, Sato K, Tsai J, Aird W, Rosenberg RD, et al: PR39, a peptide
regulator of angiogenesis. Nat Med. 6:49–55. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Carmeliet P, Dor Y, Herbert JM, Fukumura
D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R,
Maxwell P, et al: Role of HIF-1alpha in hypoxia-mediated apoptosis,
cell proliferation and tumour angiogenesis. Nature. 394:485–490.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sun L, Hao Y, Nie X, Xu J, Li Z, Zhang W,
Liu Y and Zhang X: Recombinant AAV-PR39-mediated hypoxia-inducible
factor 1α gene expression attenuates myocardial infarction. Int J
Mol Med. 33:171–177. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Weinberg MS, Samulski RJ and McCown TJ:
Adeno-associated virus (AAV) gene therapy for neurological disease.
Neuropharmacology. 69:82–88. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li ZJ and Wang RZ: rAAV vector-mediated
gene therapy for experimental ischemic stroke. Neurol India.
56:116–121. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chtarto A, Bockstael O, Tshibangu T,
Dewitte O, Levivier M and Tenenbaum L: A next step in
adeno-associated virus-mediated gene therapy for neurological
diseases: Regulation and targeting. Br J Clin Pharmacol.
76:217–232. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang P, Wu Y, Li X, Ma X and Zhong L:
Thioredoxin and thioredoxin reductase control tissue factor
activity by thiol redox-dependent mechanism. J Biol Chem.
288:3346–3358. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
An R, Xi C, Xu J, Liu Y, Zhang S, Wang Y,
Hao Y and Sun L: Intramyocardial injection of recombinant
adeno-associated viral vector coexpressing PR39/adrenomedullin
enhances angiogenesis and reduces apoptosis in a rat myocardial
infarction model. Oxid Med Cell Longev. 2017:12716702017.
View Article : Google Scholar : PubMed/NCBI
|
